MyFinsight
Home
Blog
About
Contact
Accounts receivable, net
of allowances of 3...
$273M
(12.35%↑ Y/Y)
Cash and cash
equivalents
$175M
(-52.96%↓ Y/Y)
Inventories
$152M
(-6.75%↓ Y/Y)
Other current assets
$40M
(100.00%↑ Y/Y)
Prepaid expenses
$15M
(-73.21%↓ Y/Y)
Current tax receivable
$12M
(-58.62%↓ Y/Y)
Total current assets
$667M
(-24.46%↓ Y/Y)
Deferred tax assets
$296M
(6.09%↑ Y/Y)
Property, plant and
equipment, net
$157M
(50.96%↑ Y/Y)
Long-term investments
$27M
(0.00%↑ Y/Y)
Other noncurrent
assets
$26M
(-33.33%↓ Y/Y)
Operating lease right of
use assets, net
$22M
(-40.54%↓ Y/Y)
Goodwill and other
intangible assets, net
$2M
(-71.43%↓ Y/Y)
Total assets
$1,197M
(-12.95%↓ Y/Y)
Accumulated deficit
-$280M
(31.03%↑ Y/Y)
Accumulated other
comprehensive loss
-$29M
(17.14%↑ Y/Y)
Total liabilities and
stockholders' deficit
$1,197M
(-12.95%↓ Y/Y)
Total stockholders'
deficit
-$144M
(49.47%↑ Y/Y)
Additional paid-in capital
$165M
(77.42%↑ Y/Y)
Total liabilities
$1,341M
(-19.22%↓ Y/Y)
Total current
liabilities
$779M
(-22.49%↓ Y/Y)
Long-term debt, less
current portion
$486M
(56.27%↑ Y/Y)
Accrued litigation
settlement expenses,...
$41M
(-86.20%↓ Y/Y)
Other noncurrent
liabilities
$21M
(23.53%↑ Y/Y)
Operating lease
liabilities, noncurrent
$14M
(-53.33%↓ Y/Y)
Accrued rebates and
product returns
$551M
(-18.37%↓ Y/Y)
Accounts payable and
accrued expenses
$178M
(-2.73%↓ Y/Y)
Income taxes payable
$26M
(116.67%↑ Y/Y)
Accrued litigation
settlement expenses,...
$14M
(-86.67%↓ Y/Y)
Operating lease
liabilities, current
$9M
(-18.18%↓ Y/Y)
Back
Back
Balance Sheet
indivior-logo-svg
Indivior Pharmaceuticals, Inc. (INDV)
indivior-logo-svg
source: myfinsight.com
Indivior Pharmaceuticals, Inc. (INDV)